The National Institute of Neurological Disorders and Stroke (NINDS) is offering this grant to invite current and new Clinical Sites to join the Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT). This clinical research network aims to develop and conduct multiple, scientifically sound exploratory clinical trials for neurological disorders affecting adult and/or pediatric populations. The network focuses on evaluating promising therapies, including Phase 2 trials and studies for validating biomarkers and clinical outcomes. NeuroNEXT provides a robust, standardized infrastructure to facilitate rapid protocol development and implementation. This specific funding opportunity targets institutions capable of serving as clinical research sites within this crucial network, supporting the advancement of neuroscience clinical research.
Opportunity ID: 343639
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-NS-22-031 |
| Funding Opportunity Title: | Clinical Research Sites for the Network of Excellence in Neuroscience Clinical Trials (NeuroNEXT sites) (U24 Clinical Trial Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.853 — Extramural Research Programs in the Neurosciences and Neurological Disorders |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Sep 20, 2022 |
| Last Updated Date: | Sep 20, 2022 |
| Original Closing Date for Applications: | Nov 21, 2022 |
| Current Closing Date for Applications: | Nov 21, 2022 |
| Archive Date: | Dec 27, 2022 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | $275,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | County governments State governments Others (see text field entitled “Additional Information on Eligibility” for clarification) City or township governments Small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education Special district governments Native American tribal governments (Federally recognized) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Public housing authorities/Indian housing authorities Public and State controlled institutions of higher education Independent school districts For profit organizations other than small businesses Native American tribal organizations (other than Federally recognized tribal governments) |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | The purpose of this funding opportunity announcement (FOA), issued by NINDS, is to invite currently awarded NeuroNEXT sites and potential new sites to participate as a Clinical Site in the Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT). This clinical research network develops and conducts multiple, scientifically sound, possibly biomarker-informed exploratory clinical trials evaluating the most promising therapies for neurological disorders, whether from academic, foundation or industry discoveries. Examples include Phase 2 clinical trials and clinical research studies aimed at validating biomarkers and clinical outcomes in preparation for clinical trials. The network provides a robust, standardized, and accessible infrastructure to facilitate rapid development and implementation of protocols in neurological disorders affecting adult and/or pediatric populations. While the network is not specific to one disease, it has the capacity to coordinate a cadre of specialist investigators to implement studies efficiently in response to disease-specific opportunities. This FOA solicits applications for Clinical Sites. Separate FOAs solicit applications for the Clinical Coordinating Center and the Data Coordinating Center. |
| Link to Additional Information: | https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-22-031.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH Grants Information
grantsinfo@nih.gov Email:grantsinfo@nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 343639 Full Announcement-RFA-NS-22-031 -> RFA-NS-22-031-Full-Announcement.pdf
Packages
| Agency Contact Information: | NIH Grants Information grantsinfo@nih.gov Email: grantsinfo@nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-G | Use for due dates on or after January 25, 2022 | PKG00276913 | Oct 21, 2022 | Nov 21, 2022 | View | |
| FORMS-H | Use for due dates on or after January 25, 2023 | PKG00277635 | Oct 31, 2022 | Nov 21, 2022 | View |
Package 1
Mandatory forms
343639 RR_SF424_5_0-5.0.pdf
343639 PHS398_CoverPageSupplement_5_0-5.0.pdf
343639 RR_OtherProjectInfo_1_4-1.4.pdf
343639 PerformanceSite_4_0-4.0.pdf
343639 RR_KeyPersonExpanded_4_0-4.0.pdf
343639 RR_Budget_3_0-3.0.pdf
343639 PHS398_ResearchPlan_4_0-4.0.pdf
343639 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
343639 RR_SubawardBudget30_3_0-3.0.pdf
343639 PHS_AssignmentRequestForm_3_0-3.0.pdf
Package 2
Mandatory forms
343639 RR_SF424_5_0-5.0.pdf
343639 PHS398_CoverPageSupplement_5_0-5.0.pdf
343639 RR_OtherProjectInfo_1_4-1.4.pdf
343639 PerformanceSite_4_0-4.0.pdf
343639 RR_KeyPersonExpanded_4_0-4.0.pdf
343639 RR_Budget_3_0-3.0.pdf
343639 PHS398_ResearchPlan_5_0-5.0.pdf
343639 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
343639 RR_SubawardBudget30_3_0-3.0.pdf
343639 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
